title: MMP-2 suppression abrogates irradiation-induced microtubule formation in endothelial cells by inhibiting αvβ3-mediated SDF-1/CXCR4 signaling.
abstract: The majority of glioblastoma multiforme (GBM) tumors recur after radiation (IR) treatment due to increased angiogenesis and IR-induced signaling events in endothelial cells (ECs) that are involved in tumor neovascularization; however, these signaling events have yet to be well characterized. In the present study, we observed that IR (8 Gy) significantly elevated MMP-2 expression and gelatinolytic activity in 4910 and 5310 human GBM xenograft cells. In addition, ECs treated with tumor-conditioned media (CM) obtained from IR-treated 4910 and 5310 cells showed increased microtubule formation. In view of this finding, we investigated the possible anti-angiogenic effects of MMP-2 downregulation using siRNA (pM.si) in IR-treated cells. We also determined the effect of CM obtained from mock, pSV (scrambled vector) and pMMP-2.si on endothelial cell growth and vessel formation. pM.si-CM-treated ECs showed inhibited IR-CM-induced SDF-1, CXCR4, phospho-PI3K and phospho-AKT and αvβ3 expression levels. In vitro angiogenesis assays also showed that the pM.si+IR decreased IR-induced vessel formation in ECs. Immunofluorescence and immunoprecipitation experiments indicated the abrogation of αvβ3-SDF-1 interaction in pM.si-CM-treated ECs when compared to mock or pSV treatments. External supplementation of either rhMMP-2 or rhSDF-1 counteracted and noticeably reversed pM.si-inhibited SDF-1, CXCR4, phospho-PI3K and phospho-AKT expression levels and angiogenesis, thereby confirming the role of MMP-2 in the regulation of αvβ3-mediated SDF-1/CXCR4 signaling. In addition to the in vitro results, the in vivo mouse dorsal air sac model also showed reduced angiogenesis after injection of pM.si alone or in combination with IR-treated xenograft cells. In contrast, injection of mock or pSV-treated cells resulted in robust formation of characteristic neovascularization. Collectively, our data demonstrate the role of MMP-2 in the regulation of SDF-1/CXCR4 signaling-mediated angiogenesis in ECs and show the anti-angiogenic efficacy of combining MMP-2 downregulation and IR when treating patients with GBM in the future.
authors: Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL 61605, USA.
authors: Dilip Rajasekhar
authors: DR
authors: Maddirela
authors: Divya
authors: D
authors: Kesanakurti
authors: Meena
authors: M
authors: Gujrati
authors: Jasti S
authors: JS
authors: Rao
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000378:metabolism; D017077:Culture Media, Conditioned; D042783:Endothelial Cells / Q000201:enzymology* / Q000528:radiation effects; D004730:Endothelium, Vascular / Q000201:enzymology / Q000473:pathology; D055785:Gene Knockdown Techniques; D005909:Glioblastoma / Q000098:blood supply / Q000201:enzymology / Q000532:radiotherapy*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000201:enzymology* / Q000473:pathology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D011836:Radiation Tolerance; D019718:Receptors, CXCR4 / Q000378:metabolism; D015398:Signal Transduction
chemical_list: C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D017077:Culture Media, Conditioned; D039302:Integrin alphaVbeta3; D034741:RNA, Small Interfering; D019718:Receptors, CXCR4; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2
references: Curr Opin Cell Biol. 2011 Oct;23(5):630-7
references: 21565482
references: Eur J Surg Oncol. 2005 Oct;31(8):869-74
references: 16081236
references: Oncogene. 2013 Jan 17;32(3):327-40
references: 22349830
references: Clin Cancer Res. 2003 Jun;9(6):1957-71
references: 12796357
references: Nature. 1998 Jun 11;393(6685):595-9
references: 9634238
references: Int J Cancer. 2008 Jul 15;123(2):357-364
references: 18464290
references: Biochem Pharmacol. 2001 Feb 1;61(3):253-70
references: 11172729
references: Br J Cancer. 2011 Jun 7;104(12):1805-9
references: 21587260
references: Cell Death Dis. 2012 Dec 20;3:e445
references: 23254288
references: Eur J Cancer. 1996 Dec;32A(14):2423-9
references: 9059330
references: Cancer Res. 2008 Jun 15;68(12):4736-45
references: 18559520
references: J Exp Med. 2005 Sep 19;202(6):739-50
references: 16157686
references: J Cell Biol. 2001 Oct 29;155(3):459-70
references: 11684710
references: Lancet Oncol. 2005 Jul;6(7):520-8
references: 15992701
references: Clin Cancer Res. 2002 Apr;8(4):1223-7
references: 11948136
references: J Mol Histol. 2004 Mar;35(3):233-45
references: 15339043
references: Semin Cancer Biol. 2004 Jun;14(3):171-9
references: 15246052
references: Mol Biol Cell. 2005 Sep;16(9):4153-62
references: 15987743
references: Cell. 1994 Dec 30;79(7):1157-64
references: 7528107
references: Clin Cancer Res. 2005 Sep 1;11(17):6270-9
references: 16144931
references: Eur J Pharmacol. 2006 Aug 7;542(1-3):8-15
references: 16806166
references: Int J Dev Biol. 2011;55(4-5):343-4
references: 21732277
references: Neuro Oncol. 2005 Apr;7(2):164-76
references: 15831234
references: Cancer Res. 2005 Nov 15;65(22):10159-63
references: 16287999
references: Gene Ther. 2011 Jul;18(7):692-701
references: 21368903
references: Ai Zheng. 2008 Oct;27(10):1044-9
references: 18851783
references: Cell. 1996 Aug 9;86(3):353-64
references: 8756718
references: Int J Cancer. 2010 Sep 1;127(5):1081-95
references: 20027628
references: PLoS One. 2011 May 04;6(5):e19341
references: 21573233
references: Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1536-43
references: 16863930
references: Cytokine. 2009 Dec;48(3):295-302
references: 19782578
references: Invest Ophthalmol Vis Sci. 2003 Jan;44(1):403-8
references: 12506102
references: J Mol Biol. 2005 Apr 22;348(1):43-62
references: 15808852
references: Nat Rev Cancer. 2003 Jul;3(7):489-501
references: 12835669
references: J Neurooncol. 2010 Dec;100(3):323-38
references: 20449629
references: Oncogene. 2013 Oct 24;32(43):5144-55
references: 23178493
references: Blood. 2002 Apr 15;99(8):2703-11
references: 11929756
references: Science. 1994 Apr 22;264(5158):569-71
references: 7512751
references: Cancer Res. 2003 Apr 15;63(8):1969-74
references: 12702590
references: Cancer Cell. 2004 May;5(5):429-41
references: 15144951
references: Cancer Res. 2008 Sep 15;68(18):7323-31
references: 18794119
references: J Neuropathol Exp Neurol. 1996 Nov;55(11):1143-9
references: 8939197
references: PLoS One. 2011;6(6):e20614
references: 21698233